1. Headline & Intro
Ultrahuman is back in the U.S. smart ring game, and its return says more about the future of wearables than about any single product spec. The Indian startup has secured approval for its new Ring Pro just months after an ITC ruling in favor of rival Oura effectively shut it out of the United States. In that short window, Oura tightened its grip on the market. This is no longer just a hardware race; it’s a case study in how patents, trade rules and data strategy can make or break entire categories. In this piece, we’ll unpack what Ultrahuman’s comeback really means—for Oura, for upcoming players like Apple and Samsung, and for users who are quietly turning their fingers into health dashboards.
2. The News in Brief
According to TechCrunch, Bengaluru-based Ultrahuman has received U.S. Customs and Border Protection approval to import and sell its new Ring Pro smart ring, after facing an import ban on its earlier Ring Air model following an October 2025 U.S. International Trade Commission ruling in favor of Oura.
The ban reportedly cost Ultrahuman up to $50 million in lost sales and crushed its U.S. market share from nearly a quarter of the market to low single digits. Over the same period, IDC data cited by TechCrunch shows Oura’s U.S. share climbing to about 85% of a 2.6‑million‑unit market in 2025. Ultrahuman has opened U.S. pre-orders for Ring Pro starting at $399, with shipping scheduled from May 15. The redesigned unibody metal ring was central to gaining approval and is positioned as more power-efficient with better on-device processing.
3. Why This Matters
Ultrahuman’s re-entry is significant because it exposes just how fragile competition is in young hardware categories. One IP ruling, and a market that was starting to look like a two‑horse race turned into an 85% near‑monopoly for Oura in the U.S. For a category still finding product–market fit, that level of concentration is risky: pricing power increases, innovation can slow, and users get locked into one ecosystem.
The immediate winner so far is clearly Oura. It converted Ultrahuman’s forced absence directly into share gains in the world’s largest smart ring market. It also used that time to deepen its brand as the default smart ring—especially in wellness, fertility tracking and sleep optimisation.
But the story isn’t purely positive for Oura. Ultrahuman’s ability to design around the disputed patents and quickly win Customs approval shows that legal victories can be temporary moats. Once competitors adjust their hardware and manufacturing, the basis of the ban weakens. Oura now has to defend its de‑facto leadership not with courts, but with product, data insights and partnerships.
For Ultrahuman, the comeback is both an opportunity and a stress test. It has a short window—roughly the 5–6 months it says it needs to scale up—to prove that Ring Pro is more than a litigation workaround. It must convince users that its value lies in better metabolic insights, more actionable coaching, or deeper biomarker coverage, not just another titanium circle with familiar sensors.
4. The Bigger Picture
Zooming out, this battle plugs into three bigger trends.
First, smart rings are quietly becoming the next mainstream wearable form factor after smartwatches. Rings are socially acceptable, less intrusive in sleep and fashion‑friendly. With 4.4 million units sold globally in 2025 according to IDC data cited by TechCrunch, we’re still early—but growth rates near 60% in the U.S. signal that this isn’t a niche for quantified‑self geeks anymore.
Second, we’re watching the familiar platform playbook. Oura and Ultrahuman both position their devices less as gadgets and more as data layers: continuous heart rate, HRV, sleep stages, temperature, SpO2 and movement streaming into proprietary algorithms. Hardware margins will compress; the recurring value will sit in subscriptions, coaching and integrations with insurers, clinicians and corporate wellness programs. Whoever becomes the default “health telemetry layer” on your body will have leverage far beyond the bill of materials.
Third, the legal dimension is becoming central to hardware strategy. The ITC case shows how patent portfolios can be weaponised as non-tariff barriers, especially in the U.S. For non‑U.S. companies—whether from India, China or even Europe—the lesson is harsh: market entry plans must include defensive IP strategy from day one. Ultrahuman’s pivot to a redesigned unibody ring is as much about regulatory resilience as ergonomics.
Against this backdrop, the looming question is how long Oura and Ultrahuman can enjoy this relative duopoly before the giants arrive. Apple and Samsung have already explored ring‑like patents and concepts. When they decide the ring is ready for prime time, their distribution, OS‑level integration and marketing budgets could reshape this landscape overnight.
5. The European / Regional Angle
For European users, this fight is about more than which ring has the nicer app. It is about who controls some of the most intimate health data generated in our daily lives.
Under GDPR and the coming EU AI Act, continuous biometrics—sleep, heart rate variability, temperature linked to menstrual cycles—are squarely in the “highly sensitive” zone. Oura has long targeted Europe and has a strong footprint in Nordics and DACH. Ultrahuman, pushed by the U.S. import ban, expanded more aggressively in Europe and Asia, which means EU regulators will increasingly be dealing with several non‑European companies competing for the same health data.
There is also a competitive nuance: Europe has very few large-scale ring players of its own, despite a strong medtech and sensor ecosystem in Germany, the Nordics and the UK. European startups have tended to focus either on clinical‑grade devices or generic fitness trackers, not this “prosumer health” middle ground. The result: European consumers rely on U.S. and Asian stacks for long‑term health telemetry, with limited data sovereignty.
For European insurers, employers and health systems, the Oura–Ultrahuman rivalry presents both opportunity and risk. On one hand, broader competition should improve pricing and innovation, potentially making population‑scale sleep or recovery programs more affordable. On the other, it concentrates critical health analytics in a handful of foreign, venture‑backed platforms whose business models hinge on monetising longitudinal health behaviour.
6. Looking Ahead
Over the next 12–24 months, expect three things.
First, a pricing and feature offensive in the U.S. as Ultrahuman tries to claw back share. Introductory discounts, bundles with other sensors, and more aggressive subscription tiers are almost guaranteed. Oura will have to decide whether to defend share with price cuts, feature acceleration, or tighter integration with partners in women’s health, elite sport and corporate wellness.
Second, India will become a strategically symbolic market. Oura’s entry into Ultrahuman’s home turf, as reported by TechCrunch, is less about near‑term revenue (the Indian ring segment actually shrank in 2025) and more about brand positioning in a market that could, over time, mirror the smartphone boom: enormous volume at lower ASPs. If Oura can build trust with Indian consumers now, it can shape expectations for what a “premium health ring” looks like as disposable incomes rise.
Third, the category will expand beyond rings. Ultrahuman has already teased a new wearable focused on a different biomarker. That hints at a modular future: rather than one device doing everything poorly, we may wear multiple, specialised sensors—on fingers, arms, maybe even as patches—feeding a unified software layer. For regulators and privacy advocates, that’s a nightmare scenario; for users with chronic conditions, it could be transformative.
The open questions: Will regulators treat these platforms increasingly like medical devices? Will Apple or Samsung decide to collapse the category into their own ecosystems? And will any European player step in with a privacy‑first, EU‑native alternative before the market calcifies?
7. The Bottom Line
Ultrahuman’s Ring Pro approval is less a happy ending and more the start of a second act in the smart ring saga. Oura still holds a dominant U.S. position, but its moat has been exposed as legal, not purely technological. For users, competition should mean better products—but also more pressure to hand over intimate health data to a small number of global platforms. The crucial question for the next few years: will smart rings evolve into a genuinely open health layer, or just another closed ecosystem we slide onto our fingers and forget to question?
